Literature DB >> 7663707

Reliable determination of furosine in human serum and dialysate proteins by high-performance liquid chromatography.

Y C Wu1, V Monnier, M Friedlander.   

Abstract

Furosine, formed by hydrolysis of 1-deoxy-fructosyl-lysine (fructose-lysine), is a product of the Amadori rearrangement of glucose and epsilon-NH2-lysine. Fructose-lysine can react further with tissue and circulating proteins to produce advanced glycation end-products (AGEs). Peritoneal dialysate used in the treatment of patients with end-stage renal failure contains high concentrations of glucose which may lead to intraperitoneal formation of AGEs. To quantitate the kinetics of formation and peritoneal clearance of glycated peritoneal dialysate proteins, we developed an effective approach to the measurement of furosine in clinical samples of serum and peritoneal dialysate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7663707     DOI: 10.1016/0378-4347(95)00038-k

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  3 in total

1.  Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis.

Authors:  M A Friedlander; Y C Wu; A Elgawish; V M Monnier
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

2.  Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1α and MCP-1 levels in type 2 diabetic patients.

Authors:  Pei-chun Chao; Chien-ning Huang; Cheng-chin Hsu; Mei-chin Yin; Yu-ru Guo
Journal:  Eur J Nutr       Date:  2010-03-13       Impact factor: 5.614

3.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.

Authors:  V M Monnier; O Bautista; D Kenny; D R Sell; J Fogarty; W Dahms; P A Cleary; J Lachin; S Genuth
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.